Sign in
CompletedPhase 1

Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study

Key facts

Who runs it
Yale University
Where
New Haven, United StatesSee the 2 sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
9 people enrolled
Started
15 May 2023
Ended
30 Dec 2024
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • NYX-783
  • Placebo
  • Oxycodone
Record updated
25 March 2025

Who can take part

Age
21 years to 58 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Voluntary, written, informed consent
  • full scale and verbal IQs > 80 (Shipley Institute of Living IQ Screening Test)
  • Non-treatment seeking, non-dependent, opioid-experienced participants with low, opioid use via smoking or oral pills routes and with no need for medical detoxification from opiates and without past 12-month history of overdoses or medical detoxification for opioid withdrawal
  • Participants must agree to use dual contraceptive methods during the study and refrain from donating sperm or ova during study or for 28 days after final dose of drug for ova and for 90 days after final dose of drug for sperm. Dual contraceptive methods include the use of a barrier contraceptive (i.e., condoms) in addition to another effective method that can prevent pregnancy (i.e., oral or parenteral contraceptives, intrauterine devices, spermicide, etc.)
  • Ability to understand and comply with study requirements and restrictions and provide a secondary contact if they cannot be reached

Who cannot take part

  • Regular daily prescribed use of anticonvulsants, sedatives/hypnotics, other antihypertensives, anti-arrhythmics, antiretroviral medications, naltrexone, antabuse, grapefruit juice and St. John's wort products, glucocorticoids, stimulants (amphetamine like compounds), CNS active medications (other than stabilized use of antidepressants and anti-anxiety medications), metformin, or other medications such as benzodiazepines and sedating antidepressants that in the opinion of the investigators interfere with the study
  • Received an investigational product or device within 30 days of dosing (or 5 half-lives whichever is longer)
  • Previously received NYX-783
  • History of severe COVID-19 infection requiring hospitalization, treatment with oxygen or mechanical ventilation, that may interfere with study participation as assessment by the Investigator
  • Participants who do not report an increase in subjective opioid effect, as measured by the Drug Effects Questionnaire (DEQ, see below) by minimum of 10% or more to initial challenge with oxycodone in Session 1 will be excluded from the DDI phase sessions 2-7
  • Meet current DSM-5 criteria of moderate to severe Substance Use Disorder (SUD) on either sedative, hypnotics, cocaine, methamphetamine, opiates or alcohol
  • HIV seropositivity, hepatitis or other acute ongoing infectious disease considered clinically significant by the investigator
  • Individuals with current or past history of seizure disorders
  • Current or recent diagnosis within past 6-months of Major Depressive Disorder (MDD), bipolar disorder, schizophrenia, and schizoaffective disorder
  • History of a neurodegenerative or neuro-inflammatory disorder including Huntington's, Parkinson's, Alzheimer's disease, or multiple sclerosis
  • History of gastrointestinal disease or surgery (except simply appendectomy or hernia repair), leading to impaired drug absorption
  • Heart rate ≤45 or >90 bpm at screening
  • Any participant with a medical history of Covid-19 infection (positive test) within the last 2 months, or current symptoms consistent with Covid-19 infection, as assessed by the Investigator
  • Known familial history or known presence of long QT syndrome, or a known history of past or current clinically significant arrhythmias or ischemic heart disease
  • Sensitivity, allergy, or intolerance to N-methyl-D-aspartate receptor (NMDAR) ligands including ketamine, dextromethorphan, memantine, methadone, dextropropoxyphene, or ketobemidone and magnesium. Use of NMDAR-binding drugs within 60 days prior to dosing or during the study
  • Screening QT interval corrected for heart rate (HR) by Fridericia's formula (QTcF) > 450 (males) or 470 (females) milliseconds (msec) or an ECG that is not suitable for QT measurements (e.g., poorly defined termination of T-wave in the investigator's opinion
  • Creatinine clearance <60ml/min at screening or history of renal disease as assessed by Investigator
  • Uncontrolled Type I or Type II diabetes or uncontrolled hypertension characterized by fasting blood glucose > 126 mg/dl or postprandial blood glucose > 200 mg/dl, resting systolic blood pressure >160 mm Hg or resting diastolic >100 mm Hg, or clinically significant hypotension in the judgement of the Investigator as characterized by resting systolic blood pressure <90 mm Hg or resting diastolic blood pressure <60 mm Hg
  • Impaired hepatic function characterized by a previous known diagnosis of chronic liver disease and/or the presence of:; direct bilirubin > 1.5x the upper limit of normal at screening; alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase, or gamma-glutamyl transferase (GGT) > 2x the upper limit of normal at screening
  • Daily heroin, fentanyl use requiring opiate detoxification and treatment
  • Women who are pregnant or nursing (as assessed by pregnancy tests during initial intake and upon CNRU admissions)
  • Traumatic brain injury with loss of consciousness
  • Uncorrected hypothyroidism or hyperthyroidism. Participants with compensated hypothyroidism with normal thyroid-stimulating hormone levels may be enrolled
  • Donated blood during the past 8 weeks

Where in United States

  • Cmhc/CnruNew Haven, United States
  • The Yale Stress Center: Yale UniversityNew Haven, United States

About the trial

What the trial wants to find out

This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 50 mg and 150 mg versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study in non-treatment seeking non-dependent, opioid experienced individuals with current recreational use.

The 3 groups in the trial

  • Placebo + OxycodonePlacebo, for comparison

    Participants will receive placebo with + 15 mg oxycodone then placebo + 30 mg oxycodone in separate inpatient randomized sessions in this, cross-over study over 6 experimental sessions.

    Treatment: Placebo and Oxycodone

  • NYX-783: 50 mg dose + OxycodoneExisting treatment, for comparison

    Participants will receive NYX-783 50 mg dose with + 15 mg oxycodone then NYX-783 50 mg + 30 mg oxycodone in separate inpatient randomized sessions in this, cross-over study over 6 experimental sessions.

    Treatment: NYX-783 and Oxycodone

  • NYX-783: 150 mg dose + OxycodoneExisting treatment, for comparison

    Participants will receive NYX-783 150 mg dose with + 15 mg oxycodone then NYX-783 150 mg + 30 mg oxycodone in separate inpatient randomized sessions in this, cross-over study over 6 experimental sessions.

    Treatment: NYX-783 and Oxycodone

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Evaluation of NMDA Modulator NYX-783 for OUD: Randomized, Double-blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics of NYX-783 in Combination With Oxycodone (Study 1)
Record updated
25 March 2025